Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2017-2023

  Gatti, Giorgio ^a,f   Papa, Pietro ^b   Torre, Donato ^c   Andreoni, Massimo ^d   Poggio, Antonio ^e   Bassetti, Matteo ^a   Marone, Piero ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Hospital of Biella   (Italy)

^e Hospital of Verbania   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BENZODIAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; FLUCONAZOLE; PHENOBARBITAL; RIFABUTIN;

ADULT; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; COMPARTMENT MODEL; DEMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYCOBACTERIOSIS; PRIORITY JOURNAL;

EID: 0031928115     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2017     Document Type: Article

References (31)

1. 14C-rifabutin to plasma proteins of healthy normal volunteers. Internal report no. PK/DM-3124-92-02. Adria Laboratories, Columbus, Ohio.
2. Centers for Disease Control and Prevention. 1996. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. Morbid. Mortal. Weekly Rep. 45:921-925.
3. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
4. Colborn, D., R. Lewis, and P. K. Narang. 1994. HIV disease severity does not influence rifabutin absorption., Abstr. A42, p. 39. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Colborn, D. C., R. C. Li, and P. K. Narang. 1993. Influence of gender on rifabutin kinetics. Clin. Pharmacol. Ther. 53:182.
6. DATRI (Division of AIDS Treatment Research Institute) Study Group. 1994. Coadministration of clarithromycin alters the concentration-time profile of rifabutin, abstr. A2, p. 3. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Duchene, P. 1990. Pharmacokinetics of rifabutin (LM427) in patients with alcoholic liver disease. Internal report LM 427/613i. Farmitalia Carlo Erba, Milan, Italy.
8. Engel, G., U. Hofmann, H. Heidemann, J. Cosme, and M. Eichelbaum. 1996. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59: 613-623.
9. Gatti, G., J. Flaherty, J. Bubp, J. White, M. Borin, and J. Gambertoglio. 1993. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob. Agents Chemother. 37:1137-1143.
10. Gatti, G., M. Merighi, J. Hossein, R. Casazza, S. Travaini, M. Karlsson, M. Cruciani, and D. Bassetti. 1996. Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 40:2743-2748.
11. Gordon, S. M., C. R. Horsburgh, C. A. Peoquin, J. A. Havlik, B. Metchock, L. Heifets, J. E. McGowan, and S. E. Thomson III. 1993. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J. Infect. Dis. 168:1559-1562.
12. Lake-Bakaar, G., T. Winston, D. Lake-Bakaar, N. Gupta, S. Beidas, M. Elsakr, and E. Straus. 1988. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 109: 471-473.
13. McCrea, J., D. Wyss, J. Stone, A. Carides, S. Kusma, C. Kleinbloesem, Y. Al-Hamdan, K. Yeh, and P. Deutsch. 1997. Pharmacokinetic interaction between indinavir and rifampin. Clin. Pharmacol. Ther. 61:152.
14. Mozzi, E., R. Germiniani, G. Cantaluppi, V. Marchetti, M. P. Vettaro, and A. Sardi. 1983. Human pharmacokinetics of LM 427, a new antimycobacterial agent: tissue distribution and excretion, abstr. AX0006. In Proceedings of the 13th International Congress on Chemotherapy. Egermann Druckerei Gesellschaft, Vienna, Austria.
15. Narang, P. K. 1995. Clinical pharmacology of rifabutin: a new antimycobacterial. Rev. Contemp. Pharmacother. 6:129-151.
16. Narang, P. K. 1996. Rifabutin oral absorption unaltered with progressing HIV disease. Clin. Pharmacol. Ther. 59:141.
17. Narang, P. K., R. C. Lewis, and J. R. Bianchine. 1992. Rifabutin absorption in humans: relative bioavailability and food effect. Clin. Pharmacol. Ther. 52:335-341.
18. Nightingale, S. D., D. W. Cameron, F. M. Gordin, P. M. Sullam, D. L. Cohn, R. E. Chaisson, L. J. Eron, P. D. Sparti, B. Bihari, D. L. Kaufman, J. J. Stern, D. D. Pearce, W. G. Weinberg, A. LaMarca, and F. P. Siegal. 1993. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N. Engl. J. Med. 329:828-833.
19. NONMEM Project Group. 1992. NONMEM users guides. In S. L. Beal and L. B. Sheiner (ed.). University of California at San Francisco, San Francisco.
20. Peloquin, C. A., A. A. MacPhee, and S. E. Berning. 1993. Malabsorption of antimycobacterial medications. N. Engl. J. Med. 329:1122-1123.
21. Perucca, E., R. Grimaldi, G. M. Frigo, A. Sardi, H. Monig, and E. E. Ohnhaus. 1988. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur. J. Clin. Pharmacol. 34:595-599.
22. Sardi, A. 1983. Pharmacokinetics of LM 427. Biliary excretion in man. Internal report LM 427/603i. Farmitalia Carlo Erba, Milan, Italy.
23. Shafran, S. D., J. Singer, D. P. Zarowny, P. Phillips, I. Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachlis, R. G. Lalonde, M. M. Fanning, and C. M. Tsoukas for the Canadian HIV Trials Network Protocol 010 Study Group. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, and clofazimine and ciprofloxacin. N. Engl. J. Med. 335:377-383.
24. Skinner, M. H., M. Hsieh, J. Torseth, D. Pauloin, G. Bhatia, S. Harkonen, T. C. Merigan, and T. F. Blaschke. 1989. Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 33:1237-1241.
25. Spigset, O., L. Carleborg, K. Hedenmalm, and R. Dahlqvist. 1995. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin. Pharmacol. Ther. 58:399-403.
26. Strolin-Benedetti, M., S. Stocco, M. G. Jannuzzo, and C. Efthymiopoulos. 1990. Pharmacokinetics of rifabutin in healthy volunteers after single and repeated (10 days) oral administration of 450 mg daily dose. Internal report LM 427/617i. Farmitalia Carlo Erba, Milan, Italy.
27. Tamassia, V. 1986. A dose proportionality study of rifabutin in healthy volunteers given single oral doses (300, 450, and 60 mg). Internal report LM 427/610i. Farmitalia Carlo Erba, Milan, Italy.
28. 14C-rifabutin administered orally to healthy volunteers. Internal report LM 427/609i. Farmitalia Carlo Erba, Milan, Italy.
29. Tett, S., S. Moore, and J. Ray. 1995. Pharmacokinetics and bioavaibility of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob. Agents Chemother. 39:1835-1841.
30. Trapnell, C. B., P. K. Narang, R. Li, and J. P. Lavelle. 1996. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann. Intern. Med. 124:573-576.
31. Van Der Auwera, P., T. Matsumoto, and M. Husson. 1988. Intraphagocytic penetration of antibiotics. J. Antimicrob. Chemother. 22:185-192.